BioCentury
ARTICLE | Financial News

ObsEva raises CHF60M, strikes endometriosis deal

November 24, 2015 4:00 AM UTC

ObsEva S.A. (Geneva, Switzerland) raised CHF60 million ($58.9 million) in a series B round led by new investor HBM Healthcare Investments. Also participating were new investors New Enterprise Associates, OrbiMed and Rock Springs Capital, as well as existing investors Sofinnova Partners, Sofinnova Ventures, Novo Ventures and MS Ventures.

On Nov. 20, the reproductive health company obtained ex-Asia rights to gonadotropin-releasing hormone (GnRH) antagonist KLH-2109 from Kissei Pharmaceutical Co. Ltd. (Tokyo:4547). The companies said they will develop the compound in parallel to treat endometriosis. Kissei has already completed three Phase IIa studies of KLH-2109 in Japan. ObsEva intends to start a placebo-controlled Phase 2b study in mid-2016; it has renamed the compound OBE2109. ...